Miscellaneous hematological agents:

Indications for MOZOBIL:

In combination with granulocyte colony stimulating factor (G-CSF): To mobilize hematopoietic stem cells to the peripheral blood for collection and autologous transplantation in patients with non-Hodgkin's lymphoma or multiple myeloma.


Start after 4 days' treatment with G-CSF. Give approximately 11hrs before starting apheresis. Repeat up to 4 consecutive days. Base dose on actual body weight. 0.24mg/kg SC; max 40mg/day. Renal impairment (CrCl≤50mL/min): 0.16mg/kg; max 27mg/day.


Not established.


Not for use in leukemia. May cause mobilization of tumor cells (in combination with G-CSF). Monitor blood and platelet counts (esp. neutrophils). Monitor for splenic enlargement/rupture after administration in combination with G-CSF; evaluate if left upper abdominal pain and/or scapular or shoulder pain occurs. Monitor for signs/symptoms of hypersensitivity during and after administration for at least 30mins. Embryo-fetal toxicity. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.

Pharmacologic Class:

Hematopoietic stem cell mobilizer.


May be potentiated by drugs that reduce renal function or compete for active tubular secretion.

Adverse Reactions:

Diarrhea, nausea, fatigue, inj site reactions, headache, arthralgia, dizziness, vomiting; anaphylactic shock, hypersensitivity reactions (may be serious), tumor cell mobilization, increased circulating neutrophils, decreased platelet counts, enlarged spleen, vasovagal reaction may occur.

Generic Availability:


How Supplied:

Single-use vials (1.2mL)—1

Pricing for MOZOBIL

1.2ml of 20mg/ml vial (Qty: 1)
Appx. price $6630